热门资讯> 正文

吉利德认为第二季度每股收益受到IPR & D费用的打击

2025-07-12 06:23

Gilead Sciences (NASDAQ:GILD) said that its Q2 financial results will be negatively impacted by $61M in acquired in-process research and development (IPR&D) charges, leading to a ~($0.04) reduction in GAAP and non-GAAP EPS.
The company said ~$40M of the charge is related to its partnership with Kymera Therapeutics (KYMR) announced in June to develop cancer drugs, while the other ~$21M is attributed to other collaborations and partnerships.
Non-GAAP EPS consensus for the quarter is $1.97, while GAAP EPS consensus is $1.48.
Gilead reports earnings on Aug. 1.

More on Gilead Sciences

Kymera Shrugs Off Sanofi Bust With Gilead Deal--But There Are Caveats
Gilead Sciences: Strong Buy On Pipeline Momentum And Cost Discipline
Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Arcus says Gilead-partnered cancer drug won FDA orphan status
Gilead in pact to speed up access to new HIV therapy in low-income nations

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。